Indications And Dose
Symptomatic relief of allergy such as hayfever, chronic idiopathic urticaria ▶BY MOUTH ▶Child 12–17 years: 8 mg 3 times a day ▶Adult: 8 mg 3 times a day
PDF page 315
Loading InternPractice…
Drug reference
Symptomatic relief of allergy such as hayfever, chronic idiopathic urticaria ▶BY MOUTH ▶Child 12–17 years: 8 mg 3 times a day ▶Adult: 8 mg 3 times a day
PDF page 315
Avoid in Acute porphyrias p. 1120. elderly
PDF page 315
Contra-indicated if history of hypersensitivity to triprolidine. Respiratory system
PDF page 315
→Appendix 1: antihistamines, non- sedating
PDF page 315
▶Common or very common Drowsiness. dry mouth ▶Frequency not known Dizziness. rash SIDE-EFFECTS, FURTHER INFORMATION Non-sedating antihistamines such as acrivastine cause less sedation and psychomotor impairment than the older antihistamines, but can still occur; sedation is generally minimal. This is because non-sedating antihistamines penetrate the blood brain barrier to a much lesser extent.
PDF page 315
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.
PDF page 315
Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.
PDF page 315
Avoid in severe impairment.
PDF page 315
There can be variation in the licensing of different medicines containing the same drug. Capsule ▶Benadryl Allergy Relief (McNeil Products Ltd) Acrivastine 8 mg Benadryl Allergy Relief 8mg capsules | 24 capsule p £5.45 | 48 capsule p £9.91
PDF page 315
Driving and skilled tasks Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.
PDF page 315
8 mg 3 times a day
First-line fragment. Read the complete Indications and Dose section above.
PDF page 315
8 mg 3 times a day
First-line fragment. Read the complete Indications and Dose section above.
PDF page 315